OMC
CLDI icon

Old Mission Capital’s Calidi Biotherapeutics CLDI Stock Holding History

Old Mission Capital’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-106
Closed -$125K – 1481
2022
Q3 		$125K Sell
106
-50
-32% -$59.9K ﹤0.01% 844
2022
Q2 		$186K Sell
156
-67
-30% -$79.8K 0.01% 1158
2022
Q1 		$265K Buy
+223
New +$263K 0.01% 947

Other funds holding CLDI

Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
EC
Elequin Capital New York $1.19B AUM 16.08% 1-Year Est. Return
SFM
Spartan Fund Management Toronto, Ontario, Canada $30M AUM 11.98% 1-Year Est. Return

Old Mission Capital's CLDI Position: Q4 2022 in Review

Old Mission Capital sold out of Calidi Biotherapeutics (CLDI) in Q4 2022, closing a stake of 106 shares — an estimated $125K sold.

Old Mission Capital first reported a position in CLDI in Q1 2022 and held it in 3 quarters. The position peaked at $265K in Q1 2022. 24 funds tracked by Wall St. Rank hold CLDI as of Q4 2022.

  • Old Mission Capital reported no remaining Calidi Biotherapeutics position as of Q4 2022 after selling out during the quarter.
  • Old Mission Capital sold 106 Calidi Biotherapeutics shares in Q4 2022, an estimated $125K.
  • Old Mission Capital first reported a position in Calidi Biotherapeutics in Q1 2022 and held it in 3 quarters.
  • Old Mission Capital's Calidi Biotherapeutics position peaked at $265K in Q1 2022.
  • 24 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q4 2022.

Based on Old Mission Capital's 13F filing for Q4 2022, filed 14 Feb 2023.